Rho激酶抑制剂对急性冠状动脉综合征患者血清白细胞介素-37的影响  

Effect of Rho kinase inhibitor on serum interleukin-37 in patients with acute coronary syndrome

作　　者：陈少源[1] 王执兵[1] 王磊[1] 陈銮香[1] 谢培益[1] 方红城[1] 

机构地区：[1]广东医学院附属深圳南山医院,广东深圳518052

出　　处：《岭南心血管病杂志》2015年第6期741-744,751,共5页South China Journal of Cardiovascular Diseases

摘　　要：目的通过Rho激酶(Rho kinase,ROCK)抑制剂干预急性冠脉综合征(acute coronary syndrome,ACS)患者,探讨其对血清白细胞介素37(interleukin-37,IL-37)的影响。方法用酶联免疫吸附试验(ELISA)法测定70例使用不同剂量法舒地尔的ACS患者周围静脉血清IL-37和ROCK2浓度,其中常规剂量治疗组25例、低剂量治疗组25例及未使用组20例;另选15名健康者作为对照组。结果 (1)入院时ACS组血清IL-37浓度低于健康对照组,ROCK2高于健康对照组,差异有统计学意义(P<0.05);(2)ACS组血清IL-37、ROCK2浓度在4周时与入院时比较,差异有统计学意义(P<0.05);(3)4周时ACS患者血清IL-37浓度在法舒地尔常规剂量治疗组较未使用组升高,ROCK2较未使用组降低,差异有统计学意义(P<0.05);(4)法舒地尔常规剂量治疗组左心室功能优于未使用组,差异有统计学意义(P<0.05);(5)ACS患者三组间的药物不良反应和主要心血管事件发生率在4周时比较,差异无统计学意义(P>0.05)。结论 IL-37参与了ACS的发病过程,有望作为监测ACS患者的指标;其作用可能通过ROCK通路产生。法舒地尔治疗可提高抗炎因子IL-37的浓度,改善患者左心室功能;不良反应无增加。Objectives To explore the effect of Rho kinase （ROCK） inhibitor on serum inter]eukin-37 （IL-37） by interventing acute coronary syndrome （ACS） in patients. Methods Seventy patients with ACS were randomly divided into three groups： 25 cases in conventional-dose fasudil treatment group, 25 cases in low-dose fasudil treatment group and 20 cases in non-fasudil group. There were 15 cases of healthy people as control group. Enzyme-linked immunosorbent assay （ELISA） was used to detect serum concentrations of IL-37 and ROCK2 in these patients. Results （1）At admission, serum concentration of IL-37 in ACS group was significantly lower than that in healthy control group, serum concentration of ROCK2 was significantly higher than that in healthy control group （P〈0.05）. （2） Serum concentrations of IL-37 and ROCK2 in ACS group were significantly different at the fourth week compared to those at admission （P〈0.05）. （3） At the fourth week, serum concentration of IL-37 in conventional-dose fasudil treatment group was significantly higher than that in non-fasudil group, ROCK2 was significnatly lower than that in non-fasudil group （P〈0.05）. （4） Left ventricular function in conventional-dose fasudil treatment group was obviously better than that in non-fasudil group （P〈0.05）. （5）Incidences of adverse drug reactions and major adverse cardiac events were not statistically different among the three groups of ACS patients at the fourth week （P〉0.05）. Conclusions IL-37 is involved in the pathogenesis of ACS, it can be an indicator for monitoring patients with ACS ; its effect may be produced by the ROCK pathway. Fasudil treatment can elevate the level of anti-inflammatory eytokine IL-37 and improve left ventricular function without increasing adverse reactions.

关 键 词：冠状动脉疾病 白细胞介素-37 RHO激酶 法舒地尔 

分 类 号：R541.4[医药卫生—心血管疾病]